BioCentury

7:00 AM GMT, Apr 26, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Cardio3: Showing heart

Treatments for heart failure and myocardial infarction generally address only the symptoms of the disease. Cardio3 BioSciences S.A. believes its stem cell-derived cardiopoietic cells can help repair damaged heart tissue, and says its challenge will be to get to market in order to show potential partners that the business model can make money.

Under a license from the Mayo Clinic, Cardio3 uses a cocktail of undisclosed cardiogenic factors to induce pluripotent stem cells to differentiate into cardiac progenitor cells.

The company's lead therapeutic is C-Cure, an autologous cell therapy for congestive

Read the full 896 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.